Erythropoietin Drugs Market By Drug Class (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa), By Drug Type (Biologics, Biosimilar), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Cancer, Renal Disease, Hematology, Neurology), Industry Trends, Estimation & Forecast, 2018 - 2025

September 2018

 Pages: 184

 ERC 5875


Erythropoietin Drugs Market is expected to grow with a CAGR of 7% during the forecast period of 2018 to 2025

Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone produced by kidneys, responsible for stimulating the bone marrow to produce red blood cells within the body. Erythropoietin drugs market is witnessing an impressive growth with the increasing prevalence of anemia among women, especially in the developing and under developed countries such as India, Nigeria and many others. Moreover, rising number of patients suffering from chronic diseases such as cancer and chronic kidney disease is another factor which is driving the market growth. According to American Cancer Society, in 2018, 1,735,350 new cancer cases are anticipated to be diagnosed. In addition to this, patent expiration of the branded drugs lets the generic and biosimilar manufacturers to enter the market. These drugs are cheap, and hence are affordable for every economic group of the society.

Additionally, reimbursement policies for patients is yet another factor responsible for the growth of erythropoietin drugs market. However, side effects of erythropoietin drugs is creating hesitation among the patients to adopt these drugs, thus, hampering the growth of the erythropoietin drugs market. On the other hand, favorable government initiatives in order to promote the usage of generic drugs can put forward a lucrative growth platform for the drug manufacturers involved in generic drugs. For example, the U.S. Food and Drug Administration has recently approved Retacrit (epoetin alfa-epbx) as a drug biosimilar to Epogen/Procrit (epoetin alfa) from Amgen Inc, to treat anemia caused by chronic kidney disease, chemotherapy. It is also approved to be used before and after the surgeries causing excessive blood loss, as it reduces the chances of red blood cell transfusion.

The report provides detailed qualitative and quantitative analysis of the Erythropoietin Drugs market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely drug class, drug type, distribution channel, application in each of the major regions.

Erythropoietin Drugs Market Player Analysis -

The report presents detailed analysis of major players operating in erythropoietin drugs market. Few of them include LG Life Sciences Limited, Ranbaxy Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Biocon Limited, Hoffmann-La Roche AG, Hospira Inc, Pfizer Inc, Johnson & Johnson LLC, Novartis International AG. Amgen Inc, GlaxoSmithKline plc, Merck & Co, and Wockhardt Ltd. A detailed coverage on these market players with information on their revenue from erythropoietin drugs business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Erythropoietin drugs market is segmented on the basis of drug class, drug type, distribution channel, application and geography. By drug class, the market is segmented into epoetin-alfa, epoetin-beta and darbepoetin-alfa. Based on drug type, the market is segmented into biologics and biosimilar. By distribution channel, the market is categorized as hospital pharmacy, retail pharmacy and online pharmacy. On the basis of application, the market is categorized as cancer, renal disease, hematology, neurology and others. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Erythropoietin Drugs Market Segmentation

By Drug Class
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa

By Drug Type
• Biologics
• Biosimilar

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Application
• Cancer
• Renal Disease
• Hematology
• Neurology
• Others

By geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC
• South America
o Brazil
o Rest of South America
• Rest of the World
o Middle East
o Africa

Erythropoietin Drugs Market Key Players

• LG Life Sciences Limited
• Ranbaxy Laboratories Ltd
• Teva Pharmaceutical Industries Ltd
• Biocon Limited
• Hoffmann-La Roche AG
• Hospira Inc.
• Pfizer Inc.
• Johnson & Johnson LLC
• Novartis International AG.
• Amgen Inc
• GlaxoSmithKline plc
• Merck & Co
• Wockhardt Ltd.


Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Erythropoietin Drugs Market in 2018 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2018 - 2025)?
    • Which are the leading companies in the Erythropoietin Drugs Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!